WATERTOWN, Mass.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions.
The corrected release reads:
ENANTA PHARMACEUTICALS ANNOUNCES DATA PRESENTATIONS AT THE LIVER MEETING® 2015
New data on studies of VIEKIRA PAK™, (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Genotype 1 Hepatitis C Patients
SVR4 data from new studies of Enanta’s next-generation protease inhibitor, ABT-493, in combination with AbbVie’s NS5A inhibitor, ABT-530
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that 34 abstracts from AbbVie’s chronic hepatitis C clinical development program have been accepted for presentation at the Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place November 13-17, 2015 in San Francisco.
Help employers find you! Check out all the jobs and post your resume.
